Condition: Bacterial Conjunctivitis · Sponsor: Baxis Pharmaceuticals, Inc.
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.
This description comes directly from the study's public registry record.
Director of Clinical Operations · 4349808100 · info@baxis.com
Always discuss trial participation with your own doctor first.
| Baxis Site 04 | Little Rock, Arkansas, United States | Recruiting |
| Baxis Site 24 | Huntington Beach, California, United States | Withdrawn |
| Baxis Site 19 | La Jolla, California, United States | Recruiting |
| Baxis Site 39 | Long Beach, California, United States | Recruiting |
| Baxis Site 31 | Los Angeles, California, United States | Recruiting |
| Baxis Site 38 | Los Angeles, California, United States | Recruiting |
| Baxis Site 20 | Sherman Oaks, California, United States | Terminated |
| Baxis Site 34 | Delray Beach, Florida, United States | Recruiting |
| Baxis Site 22 | Doral, Florida, United States | Terminated |
| Baxis Site 11 | Lake Worth, Florida, United States | Recruiting |
| Baxis Site 37 | Largo, Florida, United States | Recruiting |
| Baxis Site 27 | Lutz, Florida, United States | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06911424